Clinical Trial Update: Tegavivint for the Treatment of Relapsed or Refractory Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial update for tegavivint in relapsed or refractory leukemia; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Tegavivint

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Leukemia, Refractory Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING